Saniona: Potential for near-term royalties with Tesofensine - Redeye

Redeye returns with a view on Tesofensine following the positive opinion of the drug as an obesity treatment in Mexico by the technical committee of its regulatory agency. We raise our base case to again reflect the value of the asset but conclude that we at this stage have little insight into the strategy and commercialization.

Länk till analysen i sin helhet: https://www.redeye.se/research/894899/saniona-potential-for-near-term-royalties-with-tesofensine?utm_source=finwire&utm_medium=RSS